Lecanemab Autoinjector Injection, Solution
Product Images NDC 62856-222

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lecanemab Autoinjector (NDC 62856-222). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eisai Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Reduction In Brain Amyloid Beta Plaque (adjusted Mean Change From Baseline In Amyloid Beta Pet Composite, Suvr And Centiloids) In Study 1 (Lecanemab 01)

Figure 1: Reduction In Brain Amyloid Beta Plaque (adjusted Mean Change From Baseline In Amyloid Beta Pet Composite, Suvr And Centiloids) In Study 1 (Lecanemab 01)
A line graph comparing the adjusted mean change from baseline in SUVR and Centiloid units over time between placebo and a 10 mg/kg biweekly dose. Data points are shown at baseline, week 53, and week 79, with sample sizes decreasing over time. Significant differences for the 10 mg/kg group are indicated at weeks 53 and 79 (p<0.001). Error bars represent the standard error (SE).*
FDA Label Image

Principal Display Panelleqembindc 62856-215-01(lecanemab-irmb)injection500 mg/5 mL(100 mg/ml)single-dose Vial (Lecanemab 02)

Principal Display Panelleqembindc 62856-215-01(lecanemab-irmb)injection500 mg/5 mL(100 mg/ml)single-dose Vial (Lecanemab 02)
LEQEMBI (lecanemab-irmb) Injection 500 mg/5 mL (100 mg/mL) single-dose vial label. The label indicates it is for intravenous infusion only and must be diluted prior to use. It includes dosage instructions to see prescribing information and states it is manufactured by Eisai Inc.*
FDA Label Image

Principal Display Panelleqembindc 62856-215-01(lecanemab-irmb)injection500 mg/5 mL(100 mg/ml) (Lecanemab 03)

Principal Display Panelleqembindc 62856-215-01(lecanemab-irmb)injection500 mg/5 mL(100 mg/ml) (Lecanemab 03)
LEQEMBI 100 mg/mL (500 mg/5 mL) injection solution carton label for intravenous use. The label shows the proprietary name LEQEMBI and the generic name lecanemab with strength 100 mg/mL. It includes dosage instructions, storage information, manufacturer Eisai Inc., and a barcode with a QR code.*
FDA Label Image

Principal Display Panelleqembindc 62856-212-01(lecanemab-irmb)injection200 mg/2 mL(100 mg/ml)single-dose Vial (Lecanemab 04)

Principal Display Panelleqembindc 62856-212-01(lecanemab-irmb)injection200 mg/2 mL(100 mg/ml)single-dose Vial (Lecanemab 04)
Label for LEQEMBI 200 mg/2 mL (100 mg/mL) injection solution, lecanemab-irmb, for intravenous infusion only. The label states it is a single-dose vial, manufactured by Eisai Inc., with instructions to discard unused portions and follow prescribed dosing information.*
FDA Label Image

Principal Display Panelleqembindc 62856-212-01(lecanemab-irmb)injection200 mg/2 mL(100 mg/ml) (Lecanemab 05)

Principal Display Panelleqembindc 62856-212-01(lecanemab-irmb)injection200 mg/2 mL(100 mg/ml) (Lecanemab 05)
LEQEMBI (lecanemab-irmb) Injection 200 mg/2 mL (100 mg/mL) intravenous solution carton label by Eisai Inc. The label includes dosage form, strength, storage instructions, and usage warnings. It also features barcodes, NDC codes, and manufacturer details, covering a single vial per carton with discardable unused portions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.